Thus, it deserves to be explored whether, under defined conditions, rhIL-15 or small peptide IL-15Rα agonists [43,45,47] may be beneficial in the management of IFNγ-driven inflammatory immunodermatoses, where pro-inflammatory dermal M1 ΜACs play a key role in the pathogenesis, such as psoriasis [12,14,35,48] or atopic dermatitis [14,15,48] and may be counterbalanced by therapeutically enhancing the activities of resident anti-inflammatory M2 MACs [3,49]. Here, IL15RA is linked to atopic eczema.